EUCTR2021-005373-51-NL进行中（未招募）1 期
Reversal of opioid-induced respiratory depression with opioid antagonists - a study in opioid naïve individuals and chronic opioid users under real-life conditions - ROAR
eiden University Medical Center0 个研究点目标入组 24 人开始时间: 2021年10月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Healthy volunteers
- •1. Signed the informed consent form (ICF) and able to comply with the study requirements and restrictions listed therein;
- •2. Male and female subjects, age 18 to 45 years, inclusive;
- •3. Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have a negative serum pregnancy test prior to enrolment and must agree to use a medically acceptable means of contraception from screening through at least 1 month after the last dose of study drug;
- •4. Body Mass Index (BMI) 18 to 30 kg/m2, inclusive;
- •5. Healthy as defined by the Investigator, based on a medical evaluation that includes the subject’s medical and surgical history, physical examination, vital signs;
- •6. No history of substance use disorder;
- •7. No current use of any central nervous system (CNS) depressants prescribed or otherwise.
- •Chronic opioid users
- •1. Signed the consent form and able to comply with the requirements and restrictions listed therein;
- •2. Males or females age 18 to 55 years, inclusive;
- •3. Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have a negative serum pregnancy test prior to enrolment and must agree to use a medically acceptable means of contraception from screening through at least 3 months after the last dose of study drug.
- •4. BMI 18 to 32 kg/m2, inclusive;
- •5. Opioid tolerant patients administered prescription opioids at daily doses = 60 mg oral morphine equivalents (See Table 3);
- •6. Stable as defined by the Investigator, based on a medical evaluation that includes the subject’s medical and surgical history, physical examination, vital signs, 12-lead ECG, hematology, and blood chemistry;
- •7. No current use of any CNS depressants, besides opioids, prescribed or otherwise for 5 half-lives of the product before first study drug administration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •Healthy volunteers
- •1. Currently meet the criteria for diagnosis of substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria on any substance;
- •2. Any other active medical condition, organ disease or concurrent medication or treatment that may either compromise subject safety or interfere with study endpoints;
- •3. Consume, on average, >20 units/week of alcohol in men and >13 units/week of alcohol in women (1 unit = 1 glass (250 mL) beer, 125 mL glass of wine or 25 mL of 40% spirit);
- •4. Previous treatment with any prescribed medications or over-the-counter (OTC) medications (including homeopathic preparations, vitamins, and minerals) within 14 days or 5 half-lives (whichever is longer) prior to first study treatment administration;
- •5. Previous or current treatment with opioid agonist, partial agonist, or antagonist treatment within 30 days prior to the first study drug administration;
- •6. Require on-going prescription or OTC medications that are clinically relevant CYP P450 3A4 or CYP P450 2C8 inducers or inhibitors (e.g., rifampicin, azole antifungals [e.g., ketoconazole], macrolide antibiotics [e.g., erythromycin]);
- •7. Significant traumatic injury, major surgery, or open biopsy within the prior 4 weeks of informed consent;
- •8. History of suicidal ideation within 30 days prior to informed consent or history of a suicide attempt in the 6 months prior to informed consent;
- •9. Measured systolic blood pressure greater than 160 or less than 95 mmHg or diastolic pressure greater than 95 mmHg at screening;
- •10. History or presence of allergic response to fentanyl, sufentanil or naloxone;
- •11. Subjects who have demonstrated allergic reactions (e.g., food, drug, atopic reactions or asthmatic episodes) which, in the opinion of the Investigator and sponsor, interfere with their ability to participate in the trial;
- •12. Treatment with another investigational drug within 3 months prior to dosing or having participated in more than 4 investigational drug studies within 1 year prior to screening;
- •13. Site staff or subjects affiliated with, or a family member of, site staff directly involved in the study;
- •14. Require on-going prescription or over-the-counter medications that are clinically relevant CYP P450 3A4 or CYP P450 2C8 inducers or inhibitors (e.g., rifampicin, azole antifungals [e.g., ketoconazole], macrolide antibiotics [e.g., erythromycin]).
- •Chronic opioid users
- •1. Currently meet the criteria for diagnosis of moderate or severe substance use disorder according to the DSM-5 criteria on any substances other than opioids, caffeine, or nicotine;
- •2. Any active medical condition, organ disease or concurrent medication or treatment that may either compromise subject safety or interfere with study endpoints;
- •3. Consume, on average, >27 units/week of alcohol in men and >20 units/week of alcohol in women (1 unit = 1 glass (250 mL) beer, 125 mL glass of wine or 25 mL of 40% spirit);
- •4. Currently receiving medication-assisted treatment for the treatment of opioid-use disorder;
- •5. Require on-going prescription or over-the-counter medications that are clinically relevant CYP P450 3A4 or CYP P450 2C8 inducers or inhibitors (e.g., rifampicin, azole antifungals [e.g., ketoconazole], macrolide antibiotics [e.g., erythromycin]);
- •6. Significant traumatic injury, major surgery, or open biopsy within the prior 4 weeks of informed consent;
- •7. History of suicidal ideation within 30 days prior to infor
研究者
相似试验
招募中
4 期
Reversal of opioid-induced respiratory depression with opioid antagonists - a study in opioid naïve individuals and chronic opioid users under real-life conditionsPK en PD (farmacokinetiek en farmacodynamiek)opioid-induced respiratory depressionNL-OMON54257eids Universitair Medisch Centrum24
进行中（未招募）
1 期
Reversal of opioid-induced respiratory depression by ketamine in healthy volunteersRespiratory depressionMedDRA version: 19.0Level: LLTClassification code 10069144Term: Acute respiratory insufficiencySystem Organ Class: 100000004855MedDRA version: 19.0Level: LLTClassification code 10038701Term: Respiratory insufficiencySystem Organ Class: 100000004855EUCTR2016-002148-17-NLMC12
招募中
不适用
Reversal of opioid-induced respiratory depression (OIRD) by ketamine in healthy volunteersNL-OMON24921MC12
已完成
不适用
Reversal of opioid-induced respiratory depression (OIRD) by ketamine in healthy volunteers * the ORKA trialopioid-geinduceerde ademdepressieOpioid-induced respiratory depressionNL-OMON43104eids Universitair Medisch Centrum12
已完成
不适用
PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY)Patients monitored by capnoGraphYJPRN-UMIN000026993Covidien Japan Inc.1,650